Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 8/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 3/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381474 | 0.82 | OPRM1 (0.49) | TACR1SIGMAR1OPRM1TACR2 | |
| Hydrochloric Acid SCHEMBL3894145 | 0.81 | OPRM1 (0.49) | TACR1SIGMAR1OPRM1TACR2 | |
| SCHEMBL1381888 | 0.80 | TACR1 (0.52) | TACR1TACR2TACR3 | |
| SCHEMBL15190183 | 0.78 | TSHR (0.46) | TACR1SIGMAR1OPRM1CCR5TACR2 | |
| SCHEMBL5180988 | 0.78 | TSHR (0.46) | TACR1SIGMAR1OPRM1CCR5TACR2 | |
| SCHEMBL1380221 | 0.78 | TACR3 (0.51) | TACR1TACR2TACR3 | |
| SCHEMBL15190404 | 0.78 | TACR2 (0.46) | TACR1CCR5TACR2TACR3 | |
| SCHEMBL3901278 | 0.78 | SIGMAR1 (0.42) | TACR1SIGMAR1OPRM1CCR5TACR2 | |
| SCHEMBL4630849 | 0.76 | TACR1 (0.69) | TACR1CCR5TACR2TACR3 | |
| SCHEMBL1383858 | 0.76 | CCR5 (0.42) | TACR1SIGMAR1OPRM1CCR5TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773823-B1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-08-21 | — | — | EP | claimed |
| JP-4812759-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1773823-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | claimed |
| WO-2006021654-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-03-02 | — | — | WO | claimed |
| EP-1773823-B1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-08-21 | — | — | EP | disclosed |
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | ADRB3, ADRA2C, OPRK1 | TACR1 45/4885SIGMAR1 53/4885OPRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.